Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overall population, the incidence of VRAEs was significa...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2094149 |
| _version_ | 1827806383619178496 |
|---|---|
| author | Nussara Pakvisal Panot Sainamthip Nattaya Teeyapun Sutima Luangdilok Nassamon Wanlapakorn Ritthideach Yorsaeng Yong Poovorawan Piyapoom Pakvisal Thiti Susiriwatananont Nicha Zungsontiporn Virote Sriuranpong Suebpong Tanasanvimon Passakorn Wanchaijiraboon |
| author_facet | Nussara Pakvisal Panot Sainamthip Nattaya Teeyapun Sutima Luangdilok Nassamon Wanlapakorn Ritthideach Yorsaeng Yong Poovorawan Piyapoom Pakvisal Thiti Susiriwatananont Nicha Zungsontiporn Virote Sriuranpong Suebpong Tanasanvimon Passakorn Wanchaijiraboon |
| author_sort | Nussara Pakvisal |
| collection | DOAJ |
| description | The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overall population, the incidence of VRAEs was significantly lower in cancer patients than in healthy volunteers (57% vs 80%, P < .001). Because the mean age of the cancer patients was higher than the healthy volunteers (59 vs 48 years, P < .001), we analyzed age-matched comparison and found that there was no significant difference of VRAEs between two groups (74% vs 79%, P .32). Most VRAEs were of mild severity in both groups. The most common local VRAE was pain at the injection site in both groups, and the most common systemic VRAE was fatigue in the cancer cohort, while myalgia was the most common VRAE among the healthy controls. In the cancer cohort, fever was the only VRAE that led to interruption of the cancer treatment (in two cases). Among the cancer treatment types, patients undergoing chemotherapy-containing regimens had a lower likelihood of experiencing VRAEs. In summary, the overall incidence of VRAEs following ChAdOx1-nCoV-19 vaccine in actively treated cancer patients was comparable to healthy controls after adjusting for age. The VRAEs that occurred rarely interfered with the cancer treatment. These findings substantiate that vaccination with AZD1222 is safe in cancer patients undergoing treatment. |
| first_indexed | 2024-03-11T21:40:24Z |
| format | Article |
| id | doaj.art-1a3266a837cc424ba86d3a059ad64f26 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:24Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-1a3266a837cc424ba86d3a059ad64f262023-09-26T13:19:08ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.20941492094149Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controlsNussara Pakvisal0Panot Sainamthip1Nattaya Teeyapun2Sutima Luangdilok3Nassamon Wanlapakorn4Ritthideach Yorsaeng5Yong Poovorawan6Piyapoom Pakvisal7Thiti Susiriwatananont8Nicha Zungsontiporn9Virote Sriuranpong10Suebpong Tanasanvimon11Passakorn Wanchaijiraboon12Chulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalPolice General HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalChulalongkorn University and the King Chulalongkorn Memorial HospitalPhrapokklao HospitalThe study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overall population, the incidence of VRAEs was significantly lower in cancer patients than in healthy volunteers (57% vs 80%, P < .001). Because the mean age of the cancer patients was higher than the healthy volunteers (59 vs 48 years, P < .001), we analyzed age-matched comparison and found that there was no significant difference of VRAEs between two groups (74% vs 79%, P .32). Most VRAEs were of mild severity in both groups. The most common local VRAE was pain at the injection site in both groups, and the most common systemic VRAE was fatigue in the cancer cohort, while myalgia was the most common VRAE among the healthy controls. In the cancer cohort, fever was the only VRAE that led to interruption of the cancer treatment (in two cases). Among the cancer treatment types, patients undergoing chemotherapy-containing regimens had a lower likelihood of experiencing VRAEs. In summary, the overall incidence of VRAEs following ChAdOx1-nCoV-19 vaccine in actively treated cancer patients was comparable to healthy controls after adjusting for age. The VRAEs that occurred rarely interfered with the cancer treatment. These findings substantiate that vaccination with AZD1222 is safe in cancer patients undergoing treatment.http://dx.doi.org/10.1080/21645515.2022.2094149azd1222chadox1-ncov-19covid-19 vaccinesafetyadverse eventsmalignancy patientscancer treatment |
| spellingShingle | Nussara Pakvisal Panot Sainamthip Nattaya Teeyapun Sutima Luangdilok Nassamon Wanlapakorn Ritthideach Yorsaeng Yong Poovorawan Piyapoom Pakvisal Thiti Susiriwatananont Nicha Zungsontiporn Virote Sriuranpong Suebpong Tanasanvimon Passakorn Wanchaijiraboon Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls Human Vaccines & Immunotherapeutics azd1222 chadox1-ncov-19 covid-19 vaccine safety adverse events malignancy patients cancer treatment |
| title | Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls |
| title_full | Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls |
| title_fullStr | Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls |
| title_full_unstemmed | Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls |
| title_short | Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls |
| title_sort | vaccine related adverse events following azd1222 chadox1 ncov 19 covid 19 vaccine in solid malignancy patients receiving cancer treatment as compared to age matched healthy controls |
| topic | azd1222 chadox1-ncov-19 covid-19 vaccine safety adverse events malignancy patients cancer treatment |
| url | http://dx.doi.org/10.1080/21645515.2022.2094149 |
| work_keys_str_mv | AT nussarapakvisal vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT panotsainamthip vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT nattayateeyapun vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT sutimaluangdilok vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT nassamonwanlapakorn vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT ritthideachyorsaeng vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT yongpoovorawan vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT piyapoompakvisal vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT thitisusiriwatananont vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT nichazungsontiporn vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT virotesriuranpong vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT suebpongtanasanvimon vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols AT passakornwanchaijiraboon vaccinerelatedadverseeventsfollowingazd1222chadox1ncov19covid19vaccineinsolidmalignancypatientsreceivingcancertreatmentascomparedtoagematchedhealthycontrols |